Details for Patent: 7,449,464
Which drugs does patent 7,449,464 protect, and when does it expire?
Patent 7,449,464 protects LYNPARZA and is included in one NDA.
This patent has eighty-five patent family members in thirty-seven countries.
Summary for Patent: 7,449,464
| Title: | Phthalazinone derivatives |
| Abstract: | Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo. |
| Inventor(s): | Niall Morrison Barr Martin, Graeme Cameron Smith, Stephen Philip Jackson, Vincent Junior M Loh, Xiao-Ling Fan Cockcroft, Ian Timothy Williams Matthews, Keith Allan Menear, Frank Kerrigan, Alan Ashworth |
| Assignee: | Kudos Pharmaceuticals Ltd |
| Application Number: | US10/876,080 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,449,464 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 7,449,464
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | LYNPARZA | olaparib | TABLET;ORAL | 208558-001 | Aug 17, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Astrazeneca | LYNPARZA | olaparib | TABLET;ORAL | 208558-002 | Aug 17, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,449,464
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0305681.9 | Mar 12, 2003 |
International Family Members for US Patent 7,449,464
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1633724 | ⤷ Start Trial | C300726 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1633724 | ⤷ Start Trial | CR 2015 00012 | Denmark | ⤷ Start Trial |
| European Patent Office | 1633724 | ⤷ Start Trial | C20150012 00136 | Estonia | ⤷ Start Trial |
| European Patent Office | 1633724 | ⤷ Start Trial | 92680 | Luxembourg | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
